Comparative Pharmacology
Head-to-head clinical analysis: AVALIDE versus TELMISARTAN AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVALIDE versus TELMISARTAN AND HYDROCHLOROTHIAZIDE.
AVALIDE vs TELMISARTAN AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Avalide is a combination of an angiotensin II receptor blocker (irbesartan) and a thiazide diuretic (hydrochlorothiazide). Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- symporter in the distal convoluted tubule.
Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, leading to vasodilation and reduced aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
AVALIDE (irbesartan/hydrochlorothiazide) is available as tablets containing 150/12.5 mg, 300/12.5 mg, or 300/25 mg. The typical starting dose is 150/12.5 mg once daily, titrated to 300/12.5 mg once daily as needed. Maximum dose is 300/25 mg once daily.
Oral, one tablet once daily. Initial: Telmisartan 40 mg/HCTZ 12.5 mg; titrate to max 80 mg/25 mg once daily.
None Documented
None Documented
Irbesartan: 11-15 h (terminal), HCTZ: 6-15 h (terminal). Clinical context: Steady state reached in 3-5 days; allows once-daily dosing.
Telmisartan: 24 hours (terminal); supports once-daily dosing with ~3-5 days to steady state. Hydrochlorothiazide: 6-15 hours (mean 10h); prolonged in renal impairment.
Renal: HCTZ ~70% unchanged; Irbesartan ~20% unchanged, remainder as metabolites via biliary (60%) and renal (20%). Combined: Renal ~50%, biliary/fecal ~50%.
Telmisartan: >99% biliary-fecal as unchanged drug, <2% renal. Hydrochlorothiazide: ≥95% renal as unchanged drug; minimal biliary.
Category C
Category D/X
ARB and Thiazide Diuretic Combination
ARB